Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet
02:34pm, Tuesday, 12'th Aug 2025
A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improve
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)
04:47pm, Monday, 11'th Aug 2025
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF fra
The Smartest Growth Stocks to Buy With $1,000 Right Now
04:46am, Saturday, 09'th Aug 2025
What does it take to qualify as a growth stock? Probably the most important criterion is that the stock must be expected to grow significantly faster than the overall market.
5 Top Stocks to Buy in August
06:45am, Friday, 08'th Aug 2025
It's been an excellent summer for the broader stock market, with the major indexes hovering around all-time highs and strong earnings from many top companies.
The Best Stocks to Invest $1,000 In Right Now
04:40am, Thursday, 07'th Aug 2025
When dark clouds appear on the horizon, it's wise to grab an umbrella, even if the sun is still shining overhead. You'll want to be prepared in case a heavy rain is on the way.
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip
04:42am, Wednesday, 06'th Aug 2025
Vertex Pharmaceuticals (VRTX -20.61%) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
01:58pm, Tuesday, 05'th Aug 2025
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
12:35pm, Tuesday, 05'th Aug 2025
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
10:25am, Tuesday, 05'th Aug 2025
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
08:09am, Tuesday, 05'th Aug 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript
08:13pm, Monday, 04'th Aug 2025
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Charles F. Wagner - Executive VP, COO & CFO Duncan McKechnie - Corpor
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
06:30pm, Monday, 04'th Aug 2025
While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
06:15pm, Monday, 04'th Aug 2025
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.52 per share, beating the Zacks Consensus Estimate of $4.24 per share. This compares to a loss of $12.83 per share a year ago.
Vertex tops estimates on cystic fibrosis treatment strength, new products
05:40pm, Monday, 04'th Aug 2025
Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.
Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates
04:59pm, Monday, 04'th Aug 2025
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
